Apollomics enrolls first patient in Phase 3 trial of leukemia drug
Category: #health  By Mateen Dalal  Date: 2021-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Apollomics enrolls first patient in Phase 3 trial of leukemia drug

GlycoMimetics, Inc., a firm that develops molecule drugs, has recently announced that biotech company Apollomics has dosed first patient in China in a Phase 3 clinical trial of its new relapsed or refractory acute myeloid leukemia (AML) drug, APL-106 (uproleselan injection).

The Phase 3 clinical trial is part of a randomized, placebo-controlled, double-blind, bridging study program that will assess the effectiveness of uproleselan combined with chemotherapy, compared to alone chemotherapy, for treating people suffering from relapsed/refractory AML in Chinese patients.

The trial is a part of a complete development program for Apollomics in China, including a continuing Phase 1 pharmacokinetic (PK) and tolerability study.

According to sources, around 140 adult patients with primary relapsed AML (first or second untreated relapse) or refractory AML, will be enrolled for trial and eligible to receive induction chemotherapy.

Harout Semerjian, GlycoMimetics Chief Executive Officer, said that dosing of the first patient in this Phase 3 clinical trial in Greater China is a noteworthy accomplishment for Apollomics. This achievement comes in line with the recent completion of enrollment in a pivotal Phase 3 trial studying uproleselan in addition to a standard chemotherapy routine in patients with relapsed/refractory AML.

The prime endpoint for the Phase 3 trial is overall existence. Secondary outcome procedures include the duration and rate of remission and if uproleselan could lower the rate of oral mucositis, a chemotherapy-related side effect.

Apollomics expects to perform this study at around 20 blood cancer clinical research centers across China.

About Apollomics Inc.

Apollomics Inc. is a pioneering biopharmaceutical company devoted to discovering and developing monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. Apollomics has influential entities in California’s Foster City, and Hangzhou and Shanghai in China.

Source Credit - https://www.businesswire.com/news/home/20211123006145/en/ApollomicApollomics%20Inc.s-Inc.-Doses-First-Patient-in-Phase-3-Clinical-Trial-in-China-of-GlycoMimetics%E2%80%99-Uproleselan-for-the-Treatment-of-AML

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...